This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: [Figure] and their use as LTD4 antagonists.
대표청구항▼
A compound of formula (I) or a pharmaceutically acceptable salt thereof; [Figure] (I) wherein R1 is hydrogen, halo, C1-4 alkyl, C1-4 alkoxy, nitrile, optionally protected carboxy, optionally protected tetrazolyl, trihalomethyl, hydroxy-C1-4 alkyl, aldehydo, -CH2Z, -CH〓CH-Z or -CH2CH2Z, where Z is op
A compound of formula (I) or a pharmaceutically acceptable salt thereof; [Figure] (I) wherein R1 is hydrogen, halo, C1-4 alkyl, C1-4 alkoxy, nitrile, optionally protected carboxy, optionally protected tetrazolyl, trihalomethyl, hydroxy-C1-4 alkyl, aldehydo, -CH2Z, -CH〓CH-Z or -CH2CH2Z, where Z is optionally protected carboxy or optionally protected tetrazolyl; R2 is halo, nitrile, an optionally protected acid group, C1-4 alkoxy-carbonyl, or -CONR7R8 where R7 and R8 are each hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen, C1-4 alkyl, optionally substituted phenyl, or C1-4 alkyl substituted by -CONR7R8 or an optionally protected acid group; R5 is selected from the following three formulae: [Figure] where R10 is hydrogen, C1-4 alkyl, C2-6 alkenyl, C3-6 cycloalkyl or C1-4 alkyl-C3-6 cycloalkyl; R6 is hydrogen or C1-4 alkyl; each X is independently selected from, -O-(CH2)n-CR11R12-, -S-(CH2)n-CR11R12-, -CR11R12-, -CR11R12-(CH2)n-CR13R14-or -CR11〓CR12-, where R11,R12,R13 and R14 are each hydrogen or C1-4 alkyl; n is 0, 1 or 2; and Y is -O-CR15R16-, -S-CR15R16-, -CR15〓CR16-or -CR15R16-CR17R18-where R15, R16, R17 and R18 are each hydrogen or C1-4 alkyl.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.